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cific chemotherapy agents are un-
known, performance statuses of the
patients are unknown, and (as men-
tioned in the Discussion section of
the article) the use of prophylactic
cranial irradiation is unknown.
3. We agree with Prof. Quoix’s com-
ments regarding smoking history.
Analyzing OS by smoking status
alone is likely confounded by the
other prognostic factors. Moreover,
the absolute number of never smok-
ers with ED-SCLC was small (N 
93) when compared with ever smok-
ers with ED-SCLC, which likely
make the univariate analysis not
significant. However, given that th-
ere was numerical improvement in
1-year and 2-year survival estimates
of never-smokers over ever-smokers
in ED-SCLC, we included smoking
status in the Cox multivariate an-
alysis including patients with un-
known smoking status. Thus, all pa-
tients listed in Table 1 were included
in the Cox analysis and ever-smoker
status was found to be an unfavor-
able prognostic factor for survival.
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To the Editor:
We read with interest the recently
published in-depth analysis and review by
Hirsch et al.,1 on the prognostic and pre-
dictive role of histology in advanced non-
small cell lung cancer (NSCLC). In this
article, it was mentioned that high-exci-
sion repair cross-complementation group
1 (ERCC1) gene expression was associ-
ated with shorter survival in patients with
advanced NSCLC. This was however
based on the findings of a retrospective
study involving 61 patients.2 In contrast,
the International Adjuvant Lung Cancer
Trial Bioinvestigators group had found
that among the 372 patients in the control
group who did not receive adjuvant che-
motherapy after surgery for early stage
NSCLC, the 5-year overall survival (OS)
rate was significantly higher among pa-
tients with ERCC1-positive tumors than
with ERCC1-negative tumors (46% ver-
sus 39%; adjusted hazards ratio  0.66;
95% confidence intervals  0.49–0.90;
p 0.009).3 Moreover, a close correlation
has been identified between levels of
ERCC1 and ribonucleotide reductase sub-
unit M1 (RRM1). It has been demon-
strated that patients with high expressions
of both ERCC1 and RRM1 have signifi-
cantly longer OS and progression-free sur-
vival compared with those with high ex-
pressions of either of these two proteins
alone as well as compared with those with
low expression of both.4
It has been suggested that intact
DNA repair mechanisms as reflected by
high expressions of both RRM1 and
ERCC1 may represent favorable prognos-
tic factors for untreated patients with
NSCLC.5 Moreover, presence of a higher
capacity of these repair mechanisms could
serve to not only retard progression in
established cancers but also prevent can-
cer per se. This hypothesis can be
assessed by prospective studies that
compare the levels of ERCC1 and
RRM1 in patients with normal, smok-
ing-damaged, and preneoplastic bron-
chial epithelia with those patients hav-
ing established NSCLC.5
It is likely that in addition to
ERCC1 and RRM1, there are several
other genetic and molecular determinants
for treatment response and survival in
NSCLC patients, which have not yet been
clearly identified. This could be one of the
reasons why a phase III randomized trial
that assessed outcomes using ERCC1 tai-
lored chemotherapy among patients with
advanced NSCLC could not demonstrate
any difference between the genotypic and
control arms in terms of progression-free
survival and OS despite a higher response
rate in the former.6 Polymorphisms in
ERCC1 gene have been shown to affect
OS and treatment-related toxicity prev-
iously.7,8 It is possible that polymorphisms
of other genes as well could affect out-
comes in patients with NSCLC.
So, although it may be good for
patients receiving platinum compounds
and gemcitabine to have low ERCC1 and
RRM1 levels, respectively, bad for un-
treated patients to have low ERCC1 and
RRM1 levels, it is still unknown whether
the predictive and prognostic value of
ERCC1 and RRM1 expression in early
NSCLC differs compared with that in ad-
vanced disease. It would be helpful if a
gene-expression profile (metagene) model
similar to that identified for early stage
NSCLC could be developed for advanced
disease as well because it could help to
predict the risk of recurrence and survival
in patients with advanced NSCLC.9
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Wood-Smoke Exposure
as a Response and
Survival Predictor in
Erlotinib-Treated
Nonsmall Cell Lung
Cancer Patients
To the Editor:
In relation to the letter to the edi-
tor written by Cardona et al.1 published
in the Journal of Thoracic Oncology on
January 2009 referring to our article
entitled “Wood-Smoke Exposure as a Re-
sponse and Survival Predictor in Erlotinib-
treated Nonsmall Cell Lung Cancer Pa-
tients: An Open Label Phase II Study,”2 in
which Cardona et al. concluded that the
findings that we previously published are
not supported by them, some statements
should be made: their study is based ex-
clusively on an experience-established
treatment of 156 adenocarcinoma patients,
not a prospective clinical trial. Of these
156 patients, only 23% (36 patients) re-
ceived erlotinib. It does not mention at-
tachment to treatment of the patients,
which might be an issue, considering
that those exposed to wood-smoke gen-
erally belong to lower socioeconomic
status than those who have no history
of exposure and depend on study in-
clusion to receive treatment.
Moreover, of the erlotinib-treated
patients, just nine of them had wood-
smoke exposure (WSE) history and seven
of them also had smoking history for an
average of 14 years. Our hypothesis about
nonsmall cell lung cancer patients with
WSE and their response to tyrosine kinase
inhibitors treatment suggests that the path-
ways involved in carcinogenesis in WSE
patients and smokers are different, reason
for which nonsmall cell lung cancer de-
velopment could be attributed solely to
WSE in two patients of their series. There-
fore, the sample is not representative.
Furthermore, there is a mistake in
their statistical analysis. Cardona et al.
states a 5% response rate to erlotinib in
WSE patients with a sample size of
merely nine patients, which corresponds
to 0.45 patients, assuming that only one
patient had shown response it would be
equal to 11.11% of patients.
Also, their reported response rate
in non-WSE patients, including smokers
and nonsmokers, is of 47%, which is
strikingly high and is different from data
that have been previously reported by
Shepherd et al.3 in a phase III study that
included 731 patients with a response
rate of 8.9% and, exclusively, 29% of
patients in the adenocarcinoma subtype.
Their rate of response is not comparable
either with the TRUST4 study that in-
vestigated the extended use of erlotinib
in 5448 patients with a reported response
rate of 12%. However, this information is
consistent with our finding of a response
rate of 12.3% in non-WSE patients. We
would welcome the authors’ clarification
of their numbers in case we have misin-
terpreted them.
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Esophageal Ultrasound-
Controlled Fine Needle
Aspiration for Staging
of Mediastinal Lymph
Nodes in Patients with
Resectable Lung
Cancer: Do We Always
See the Reality?
To the Editor:
Accurate mediastinal lymph node
staging is pivotal in the staging and
treatment of non-small cell lung can-
cer.1,2 Echoendoscopic needle aspira-
tion is a minimally invasive staging
technique with a good sensitivity and
100% specificity. However, physicians
performing and relying on esophageal
ultrasound-controlled fine needle aspi-
ration (EUS-FNA) should be aware of
potential hurdles related to this tech-
nique such as
Parenchymal lung lesions adjacent to
the esophagus can be sampled and
care must be taken in their radio-
graphic and cytologic interpretation.
Lymphocytes in an needle aspiration
sample do not always indicate a lymph
node was sampled.
EUS-FNA may allow sampling of hilar
lymph nodes.
As such, EUS-FNA may result in clini-
cal overstaging (N2 instead of N0 or N1)
having an important impact on patient
treatment and prognosis. Here, we
present two cases illustrating potential
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